



Lexaria Bioscience Corp. | CSE:LXX | OTCQB:LXRP

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. Cannabinoids are poorly absorbed by the body's gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness.

The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

Lexaria's proprietary technology delivers the following advantages for cannabinoid edibles:

- 1) **Masks taste** – eliminates the undesired taste in cannabinoid edibles, enabling zero-sugar formats.
- 2) **Reduces time of onset** – effects are felt within 15-20 min vs. 60-120 min.
- 3) **Increases bio-absorption** – by 5 – 10X, to equate that of inhalation.

Business Model:

- 1) **Out-license (royalty)** the technology to third-party partners / distributors. Range: 5-10% of gross sales. Six deals signed/pending (3 definitive agreements, 4 LOI/MOU's pending).
- 2) **Product Sales** - Lexaria sells hemp oil **CBD** (cannabidiol) products. Lexaria's branded protein energy bars are excellent for energy, fiber and protein. **ViPova™** branded premium teas deliver CBD in several flavors. **TurboCBD™** hemp oil capsules are formulated with Ginseng & Ginkgo for enhanced focus and memory.



Patent Portfolio - 18 patent applications filed in US, International (under the Patent Cooperation Treaty), and national filings in 44 countries. Patents include both method and composition of matter claims. First patent issued by USPTO, Oct 25, 2016: "Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof". Additional patent issuances are expected to follow, including THC. Other molecules are also captured within the patent applications and represent future research opportunities. These include: Nicotine, Fat Soluble Vitamins (e.g., A, D, K & E), NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen).

Collaborative Research Agreement with **National Research Council** to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions.



Key Executives:

Chris Bunka - Chairman & CEO.

Serial entrepreneur, extensive experience in the capital markets, corporate governance, M&A and finance.

John Docherty, M.Sc. - Director & President.

20 yr. senior executive in the pharmaceutical and bioscience M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto.

Mr. Ted McKechnie – Director.

Senior entrepreneurial executive with extensive senior management & board experience in the consumer goods industry in National and Retail brands. Former President and COO of Maple Leaf Foods.

Stock Information:

Trading symbol: CSE:LXX, OTCQB:LXRP

Shares o/s: 67m, (f/d: 79m)

Mgmt & Insiders: 14m (21%)

Recent price: C\$0.50 / US\$0.40

